Sharon P. Klahre
Contacto de Relaciones con Inversores en SYNDAX PHARMACEUTICALS, INC. .
Origen de la red de primer grado Sharon P. Klahre.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Biotechnology | 17 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Sharon P. Klahre a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| The Salk Institute for Biological Studies | College/University | Corporate Officer/Principal | |
| AVANIR PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| TRAWS PHARMA, INC. | Biotechnology | Corporate Officer/Principal | |
| MERSANA THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Chief Operating Officer | |
| RESPONSE GENETICS, INC | Pharmaceuticals: Major | Director/Board Member | |
| TESARO INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Pennsylvania | College/University | Doctorate Degree | |
| George Washington University | College/University | Undergraduate Degree | |
| Texas Lutheran University | College/University | Undergraduate Degree | |
| University of Birmingham | College/University | Doctorate Degree | |
| Georgetown University | College/University | Undergraduate Degree | |
| Baylor College of Medicine | College/University | Doctorate Degree | |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Other Consumer Services | Corporate Officer/Principal | |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Trinity College, Cambridge | College/University | Undergraduate Degree | |
BioSight Ltd.
 BioSight Ltd. Miscellaneous Commercial ServicesCommercial Services BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal. | Miscellaneous Commercial Services | Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Graduate Degree Masters Business Admin | |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Biotechnology | Chairman | |
| TOBIRA THERAPEUTICS INC | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
| ARVINAS, INC. | Biotechnology | Director/Board Member | |
| CODIAK BIOSCIENCES | Pharmaceuticals: Major | Director/Board Member | |
| NEXTCURE, INC. | Pharmaceuticals: Major | Director/Board Member | |
ImmunoMet Therapeutics, Inc.
 ImmunoMet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImmunoMet Therapeutics, Inc. operates as a development-stage biopharmaceutical company that develops and commercializes novel oncology products. It offers novel technology that designed to disrupt cancer cell growth and enhance anti-cancer immunity. The company was founded in July 2015 and is headquartered in Houston, TX. | Pharmaceuticals: Major | Director/Board Member | |
| ONCORUS, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| XILIO THERAPEUTICS, INC. | Pharmaceuticals: Major | President | |
Alliance for Clinical Research Excellence & Safety
 Alliance for Clinical Research Excellence & Safety Miscellaneous Commercial ServicesCommercial Services Alliance for Clinical Research Excellence & Safety is a non-governmental organization that builds, implements, and maintains comprehensive systems. The non-profit company is based in Cambridge, MA. The company was founded by Greg Koski. | Miscellaneous Commercial Services | Director/Board Member | |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Miscellaneous Commercial Services | Chairman | |
| ADYNXX, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Transposon Therapeutics, Inc.
 Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Photys Therapeutics, Inc.
 Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Medical Specialties | Director/Board Member | |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Pharmaceuticals: Major | Chief Executive Officer | |
| CARISMA THERAPEUTICS, INC. | Biotechnology | Director/Board Member |
Estadísticas
Internacional
| Estados Unidos | 45 |
| Reino Unido | 4 |
| Israel | 2 |
| Bermudas | 2 |
Sectorial
| Health Technology | 32 |
| Consumer Services | 12 |
| Commercial Services | 7 |
| Finance | 3 |
Operativa
| Director/Board Member | 90 |
| Corporate Officer/Principal | 40 |
| Independent Dir/Board Member | 33 |
| Chairman | 21 |
| Chief Executive Officer | 20 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Pierre Legault | 45 |
| Dennis Podlesak | 27 |
| Briggs Morrison | 26 |
| Jennifer Jarrett | 18 |
| Keith Katkin | 16 |
| Michael Metzger | 13 |
| William Meury | 12 |
| Martin Huber | 10 |
| Keith Goldan | 10 |
| Kevin McManus | 9 |
| Luke Albrecht | 6 |
| Catherine Madigan | 5 |
| Steve M. Sabus | 5 |
| Neil Gallagher | 5 |
| Peter Ordentlich | 4 |
- Bolsa de valores
- Insiders
- Sharon P. Klahre
- Conexiones Empresas
